Akari Therapeutics Plc Files 8-K on Shareholder Vote

TL;DR

AKTX filed an 8-K for a shareholder vote on June 28th.

AI Summary

Akari Therapeutics Plc filed an 8-K on July 1, 2024, reporting on a matter submitted to a vote of security holders as of June 28, 2024. The filing details the company's corporate structure and previous name changes, including its former names Celsus Therapeutics Plc and Morria Biopharmaceuticals PLC.

Why It Matters

This filing indicates a formal process involving shareholder decisions, which can impact corporate governance and future strategic directions for Akari Therapeutics.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure regarding a shareholder vote and does not appear to contain new material financial or operational information.

Key Players & Entities

• Akari Therapeutics Plc (company) — Registrant
• Celsus Therapeutics Plc. (company) — Former Company Name
• Morria Biopharmaceuticals PLC (company) — Former Company Name
• June 28, 2024 (date) — Date of earliest event reported
• July 1, 2024 (date) — Filing Date

FAQ

Key Financial Figures

• $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn

Filing Documents

• aktx-20240628.htm (8-K) — 81KB
• 0000950170-24-079669.txt ( ) — 301KB
• aktx-20240628.xsd (EX-101.SCH) — 95KB
• aktx-20240628_htm.xml (XML) — 6KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 27, 2024, Akari Therapeutics, Plc (the "Company") held its 2024 Annual General Meeting (the "Annual General Meeting"). Proxies were solicited pursuant to the Company's definitive proxy statement filed on June 3, 2024 (the "Proxy Statement"), with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended. The number of ordinary shares entitled to vote at the Annual General Meeting was 15,847,391,523. The number of ordinary shares present or represented by valid proxy at the Annual General Meeting failed to establish a quorum for the Annual General Meeting. Accordingly, the Annual General Meeting was adjourned to June 28, 2024 (the "Adjourned Annual General Meeting"). The Adjourned Annual General Meeting duly proceeded in accordance with the provisions of the articles of association of the Company and all matters submitted to a vote of the Company's shareholders at the Adjourned Annual General Meeting were approved and the director nominees were elected. The voting results below are final and reported in ordinary shares. Ordinary Resolution Votes For Votes Against Votes Withheld Broker Non-Votes To receive the report of the Board of Directors and the accounts for the year ended December 31, 2023, together with the report of the statutory auditor and the strategic report. 6,311,484,728 33,260 , 000 138,680,000 – To approve the Board of Directors' Remuneration Report (excluding the Board of Directors' Remuneration Policy), as set out in the Company's annual report and accounts for the financial year ended December 31, 2023. 6,303 , 638,728 36,882,000 142,904 , 000 – To re-elect Donald Williams as a director of Akari, as a Class A Director as stated in Article 18.2.1 of the Company's articles of association (the "Articles"). 5 , 692 , 126 , 728 747,748,000 43 , 550 , 000 – To re-elect Michael Grissinger a

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: July 1, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR